Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Boost in Genomic Testing, Multidisciplinary Input Needed for Personalized Lung Cancer Care

November 5th 2021

Nagashree Seetharamu, MD, MBBS, discusses the importance of early and frequent genomic testing in patients with lung cancer, as well as remaining challenges faced in clinical practice and efforts being made to overcome them.

Research With Cellular Therapy Ramps Up in Mesothelioma

November 5th 2021

Marjorie G. Zauderer, MD, previews some of the new approaches in mesothelioma.

Recent Updates in EGFR-Mutant NSCLC Treatment Landscape

November 5th 2021

Experts in lung cancer provide insight on recent updates from the ESMO Congress 2021 for the treatment of EGFR-mutant NSCLC.

Sequencing Treatments in EGFR-Mutant NSCLC

November 5th 2021

Vamsidhar Velcheti, MD, and Stephen Liu, MD, discuss their treatment approaches for patients with EGFR-mutant NSCLC who progress on osimertinib.

TROPION-PanTumor01 Study Design and Primary Data Analysis

November 4th 2021

Drs Heist and Peters examine data from the lung cohort of TROPION-PanTumor01 study that focused on dopotomab deruxtecan (Dato-DXd) as an antibody-drug conjugate therapy option.

NSCLC: Standard Treatment Approaches for EGFR Exon 20 Insertion Mutations

November 4th 2021

Current standard-of-care approaches toward the management of patients with non–small cell lung cancer with EGFR exon 20 insertion mutations.

EGFR Exon 20 Insertion Mutations as a Therapeutic Target in NSCLC

November 4th 2021

In the setting of non–small cell lung cancer, experts consider the importance of EGFR exon 20 insertion mutations as a therapeutic target.

Association of Community Cancer Centers Announces Findings of National Initiative to Support Quality Care for Stage III and IV NSCLC

November 2nd 2021

The Association of Community Cancer Centers in collaboration with AstraZeneca, a global, science-led biopharmaceutical company, has announced the findings of a national quality care initiative for patients with stage III and stage IV non-small cell lung cancer.

Dr. Sabari on Selecting Between Available ALK inhibitors in ALK+ NSCLC

November 1st 2021

Joshua K. Sabari, MD, discusses selecting between available ALK inhibitors in ALK-positive non–small cell lung cancer.

Rapid Readouts: Larotrectinib Prior Therapy and Performance Status Outcomes in Patients With Non-CNS TRK Fusion Cancer

November 1st 2021

Alexander Drilon, MD, discusses prior therapy and performance status outcomes for larotrectinib in patients with non-CNS TRK fusion cancer that were presented at the European Society of Medical Oncology 2021 annual meeting.

Rapid Readouts: Efficacy and Safety of Larotrectinib in Patients With Tropomyosin Receptor Kinase (TRK) Fusion-Positive Lung Cancer

November 1st 2021

Alexander Drilon, MD, discusses the efficacy and safety data of larotrectinib in patients with tropomyosin receptor kinase (TRK) fusion-positive lung cancer that was presented at the World Cancer Lung Conference 2021 annual meeting.

Clinical Management of RET+ Advanced NSCLC

November 1st 2021

Mark Socinski and Stephen Liu describe the current treatment options for patients with RET+ NSCLC. They also summarize recent clinical data for agents that target RET.

RET Alterations in Advanced NSCLC

November 1st 2021

Ben Levy, Mark Socinski, and Stephen Liu explain the role of a RET alteration in NSCLC and its value as a targetable biomarker.

Larotrectinib Yields Promising Efficacy in NTRK+ Lung Cancer, Is Active Against CNS Metastases

October 30th 2021

Jessica J. Lin, MD, discussed the impact of larotrectinib in patients with NTRK fusion–positive lung cancer, and the importance of further understanding mechanism of resistance to targeted therapies.

Dr. Burns on Key Advances Made in RET+ NSCLC

October 29th 2021

Timothy F. Burns, MD, PhD, discusses key developments in the frontline treatment of patients with RET-positive non–small cell lung cancer.

Defining Trop-2 and Antibody-Drug Conjugates in NSCLC

October 29th 2021

Rebecca Suk Heist, MD, MPH, and Solange Peters, MD, PhD, define Trop-2 in relation to treatments for non-small cell lung cancer and discuss what antibody-drug conjugates are being developed to target it.

Dr. Girard on the Next Steps With Durvalumab in NSCLC

October 29th 2021

Nicolas Girard, MD, discusses the next steps with durvalumab in non–small cell lung cancer.

Dr. Johnson on the Potential of TROP2 as a Target for All-Comers With Solid Tumors

October 29th 2021

Melissa L. Johnson, MD, discusses the potential utility of TROP2 as a therapeutic target for all-comers with solid tumor malignancies.

CT-Based Imaging Demonstrates Utility for Early COVID-19 Identification in Lung Cancer

October 29th 2021

Routine computed tomography-based imaging scans identified abnormal ground-glass opacities and infiltrates indicative of COVID-19 in patients with lung cancer undergoing radiation therapy, enabling earlier diagnosis, treatment, and risk reducing measures.

Hollings Researcher Finds Surprising Results in COVID-19-Positive Lung Cancer Patients

October 29th 2021

MUSC Hollings Cancer Center researcher and radiation oncologist Graham Warren, MD, PhD, published a new study in the Journal of Thoracic Oncology detailing new findings and early markers of COVID-19 in lung cancer patients.